
**Biological evaluation of medical
devices —**

**Part 22:
Guidance on nanomaterials**

*Évaluation biologique des dispositifs médicaux —
Partie 22: Lignes directrices sur les nanomatériaux*



This document is a preview generated by EBS



COPYRIGHT PROTECTED DOCUMENT

© ISO 2017, Published in Switzerland

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Ch. de Blandonnet 8 • CP 401
CH-1214 Vernier, Geneva, Switzerland
Tel. +41 22 749 01 11
Fax +41 22 749 09 47
copyright@iso.org
www.iso.org

Contents

Page

Foreword	v
Introduction	vi
1 Scope	1
2 Normative references	2
3 Terms and definitions	2
4 General principles	5
4.1 General considerations	5
4.2 Biological evaluation of nanomaterials	6
4.3 Categorization of nanomaterials	6
4.4 Nanomaterial equivalence	8
5 Characterization of nanomaterials	8
5.1 General considerations	8
5.2 Characterization parameters and methods	10
5.3 Use of reference materials	14
6 Sample preparation	15
6.1 General considerations	15
6.2 Special considerations for nanostructured materials	15
6.3 Special considerations for nano-objects	15
6.4 Identity, storage and stability of stock nanomaterials	17
6.5 Description of chemical composition of stock and dosing dispersions	17
6.6 Characterization of stock dispersions	18
6.7 Characterization of dosing solutions prepared from stock dispersions	18
6.8 Dose metrics	19
6.9 Additional considerations	19
6.9.1 Endotoxin	19
6.9.2 Sterilization	20
7 Release of nano-objects from medical devices	21
7.1 General considerations	21
7.2 Degradation products	22
7.3 Release of nano-objects by wear	22
7.4 <i>In situ</i> processing	22
8 Toxicokinetics	22
8.1 General considerations	22
8.2 Factors influencing the toxicokinetics	23
8.2.1 Physicochemical properties	23
8.2.2 Biomolecular adsorption	24
8.2.3 Exposure route	25
8.2.4 Dose	25
8.2.5 Species and gender	25
8.2.6 Measurement techniques	26
9 Toxicological evaluation	26
9.1 General considerations	26
9.2 <i>In vitro</i> cytotoxicity testing	27
9.2.1 General considerations	27
9.2.2 Consideration of nanomaterial interference with the assays	28
9.2.3 Consideration of relevant dose and dose metrics	28
9.2.4 Consideration of nano-object kinetics	28
9.3 Genotoxicity, carcinogenicity and reproductive toxicity	29
9.3.1 General considerations	29
9.3.2 <i>In vitro</i> genotoxicity tests	30
9.3.3 <i>In vivo</i> genotoxicity tests	31

9.3.4	Carcinogenicity.....	32
9.3.5	Reproductive toxicity.....	32
9.4	Immunotoxicity, irritation and sensitization.....	33
9.4.1	General considerations.....	33
9.4.2	Immunotoxicity.....	33
9.4.3	Sensitization.....	34
9.4.4	Irritation.....	35
9.5	Haemocompatibility.....	36
9.5.1	General considerations.....	36
9.5.2	Complement system activation.....	37
9.5.3	Specific considerations for haemocompatibility testing.....	37
9.6	Systemic toxicity.....	37
9.7	Pyrogenicity.....	38
9.8	Implantation.....	39
10	Presentation of characterization and test results.....	39
11	Risk assessment.....	40
11.1	General considerations.....	40
11.2	Exposure assessment.....	42
11.3	Biological hazard identification.....	43
11.4	Risk estimation.....	44
11.5	Risk evaluation.....	44
12	Biological evaluation report.....	44
	Bibliography.....	46

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL: www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 194, *Biological and clinical evaluation of medical devices*.

A list of all parts in the ISO 10993 series can be found on the ISO website.

Introduction

This document is intended as guidance for the biological evaluation of medical devices that contain, generate or are composed of nanomaterials. Multiple definitions have been developed for the term nanomaterial. For the purposes of this document, the ISO definition will be used: A material is considered a nanomaterial when it has a size at the nanoscale including external and internal dimensions, i.e. when it has a size or is composed of structures with a length of approximately between 1 nm and 100 nm (ISO/TS 80004-1:2015). For regulatory purposes, it is advisable to check if specific national or regional regulatory definitions are applicable. It should be realized that other characteristics (e.g. nanospecific properties) might also be included in such definitions.

Morphological structures created on the surface of a medical device can also have sizes in the nanoscale. Therefore, possible effects of such structures on the biological response to the device also need to be considered.

Nano-objects having a length range from 1 nm to 100 nm can be generated during the life cycle of a medical device, so the evaluation of possible adverse effects due to the generation of nano-objects either from preparation, use, wear or degradation of medical devices needs to be addressed. This applies to medical devices manufactured using nanomaterials and medical devices that are manufactured not using nanomaterials but having the potential to generate nanoscale wear and/or degradation particles. For the biological evaluation of medical devices, knowledge on the potential generation and/or release of nano-objects from such materials is essential.

The procedures as described in the ISO 10993 series for the biological evaluation of medical devices can be used for the biological evaluation of those medical devices that contain nano-objects that are not released from such a device as they are an integrated part of the device. However, when release of the nano-objects is possible, a safety evaluation should also be performed on the released nano-objects. In addition to evaluating a medical device, nanomaterial components or constituents can also be separately evaluated.

This document provides trained professionals, in the context of medical device evaluation, a general approach to biological evaluation of nanomaterials and addresses how the other parts of the ISO 10993 series can be used when dealing with the evaluation of nanomaterials. It is likely that the various assays as described in the ISO 10993 series are not always appropriate as such in the testing of nanomaterials. Nanomaterials by themselves can be present as powders or colloid dispersions, but also can be present in medical devices while incorporated in a matrix, as nanostructured material or as surface structures on materials and/or medical devices. In general, nanomaterials themselves need to be evaluated instead of extracts as usually used when testing biomaterials or medical devices. Nanomaterials pose specific challenges when applying test systems commonly used for medical device evaluation and when interpreting test results.

The field of nanotechnology, development of nanomaterials and the evaluation of potential toxicity of such materials are emerging fields and this document represents only the knowledge at the time of writing. Although appropriate tools and methods for evaluation of nanomaterials are still under development, data on the characteristics and biological effects of nanomaterials should be provided in order to address safety issues in their application in the medical device field, taking into consideration a risk/benefit analysis.

This document provides guidance on how to perform a biological evaluation for those medical devices that contain, generate, or are composed of nanomaterials within a risk management process as described in ISO 10993.

Biological evaluation of medical devices —

Part 22: Guidance on nanomaterials

1 Scope

This document describes considerations for the biological evaluation of medical devices that are composed of or contain nanomaterials. In addition, this guidance can also be used for the evaluation of nano-objects generated as products of degradation, wear, or from mechanical treatment processes (e.g. *in situ* grinding, polishing of medical devices) from (components of) medical devices that are manufactured not using nanomaterials.

This document includes considerations on the:

- characterization of nanomaterials;
- sample preparation for testing of nanomaterials;
- release of nano-objects from medical devices;
- toxicokinetics of nano-objects;
- biological evaluation of nanomaterials;
- presentation of results;
- risk assessment of nanomaterials in the context of medical device evaluation;
- biological evaluation report;
- nanostructures on the surface of a medical device, intentionally generated during the engineering, manufacturing or processing of a medical device.

The following are excluded from this document:

- natural and biological nanomaterials, as long as they have not been engineered, manufactured or processed for use in a medical device;
- intrinsic nanostructures in a bulk material;
- nanostructures on the surface of a medical device, generated as an unintentional by-product during the engineering, manufacturing or processing of a medical device.

NOTE Examples of unintentional nanostructures on the surface of a medical device are extrusion draw lines and machining/tool marks.

This document is intended to provide a general framework and highlights important aspects which need to be considered when assessing the safety of medical devices composed of, containing and/or generating nano-objects. Additionally, the document identifies several common pitfalls and obstacles which have been identified when testing nanomaterials compared to bulk materials or small molecule chemical species. As a technical report (TR), this document represents the current technical knowledge related to nanomaterials. No detailed testing protocols are outlined or provided. This document can serve as a basis for future documents containing detailed protocols with a focus on nanomaterial testing.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10993 (all parts), *Biological evaluation of medical devices*

ISO/TR 13014, *Nanotechnologies — Guidance on physico-chemical characterization of engineered nanoscale materials for toxicologic assessment*

ISO 14971, *Medical devices — Application of risk management to medical devices*

3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 10993 (all parts), ISO/TR 13014 and ISO 14971 and the following apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <http://www.iso.org/obp>
- IEC Electropedia: available at <http://www.electropedia.org/>

3.1 aggregate

particle comprising strongly bonded or fused particles where the resulting external surface area is significantly smaller than the sum of calculated surface areas of the individual components

Note 1 to entry: The forces holding an aggregate together are strong forces, for example, covalent bonds, or those resulting from sintering or complex physical entanglement.

Note 2 to entry: Aggregates are also termed secondary particles and the original source particles are termed primary particles.

[SOURCE: ISO/TS 80004-2:2015, 3.5, modified — definition and Note 1 to entry changed]

3.2 agglomerate

collection of weakly bound particles or *aggregates* (3.1) or mixtures of the two where the resulting external surface area is similar to the sum of the surface areas of the individual components

Note 1 to entry: The forces holding an agglomerate together are weak forces, for example van der Waals forces, or simple physical entanglement.

Note 2 to entry: Agglomerates are also termed secondary particles and the original source particles are termed primary particles.

[SOURCE: ISO/TS 80004-2:2015, 3.4]

3.3 engineered nanomaterial nanomaterial (3.7) designed for a specific purpose or function

[SOURCE: ISO/TS 80004-1:2015, 2.8]

3.4 incidental nanomaterial nanomaterial (3.7) generated as an unintentional by-product of a process

Note 1 to entry: The process includes manufacturing, bio-technological or other processes.